Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0243026 (sepsis)
 52,417 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Acteoside is a phenylpropanoid glycoside with antioxidant and anti-inflammatory activities. We isolated acteoside from Buddlejae Flos, which has been used as a traditional medicine to treat conjunctive congestion and sepsis. The effect of acteoside on the expression of the inducible nitric oxide synthase (iNOS) gene was examined in the Raw264.7 macrophage cell line. An acteoside pretreatment significantly inhibited the release of NO in the cells treated with lipopolysaccharide (LPS). Western blot and RT-PCR analyses revealed that acteoside inhibited the LPS-induced levels of the iNOS protein and mRNA. Activation of the nuclear factor-kappaB (NF-kappaB) and the activator protein-1 (AP-1) is the key step in the signaling pathways mediating iNOS induction. In this study, acteoside selectively suppressed AP-1 activation, which may be essential for iNOS induction in the LPS-treated macrophages. The inhibitory effect of AP-1 activation by acteoside may be associated with the anti-inflammatory effects of Buddlejae Flos.
 ...
PMID:Inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by acteoside through blocking of AP-1 activation. 1574 Aug 96

Acteoside, an active phenylethanoid glycoside, has been used traditionally as an anti-inflammatory agent. The molecular mechanism by which acteoside reduces inflammation was investigated in lipopolysaccharide (LPS)-induced Raw264.7 cells and in a mouse model of cecal ligation and puncture (CLP)-induced sepsis. In vitro, acteoside inhibits high mobility group box 1 (HMGB1) release and iNOS/NO production and induces heme oxygenase-1 (HO-1) expression in a concentration-dependent manner, while HO-1 siRNA antagonizes the inhibition of HMGB1 and NO. The effect of acteoside is inhibited by the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 and Nfr2 siRNA, indicating that acteoside induces HO-1 via p38 MAPK and NF-E2-related factor 2 (Nrf2). In vivo, acteoside increases survival and decreases serum and lung HMGB1 levels in CLP-induced sepsis. Overall, these results that acteoside reduces HMGB1 release and may be beneficial for the treatment of sepsis.
 ...
PMID:Acteoside improves survival in cecal ligation and puncture-induced septic mice via blocking of high mobility group box 1 release. 2356 99